Concept of Lead Time

Definition

Background - Why Lead Time Matters in Screening

• The severity of the disease
• The success of treatment in reversing the disease process

The Model for Early Detection Programmes (Fig. 1)

• Line A = Usual outcome without screening
• Line B = Outcome when disease is detected at the earliest possible moment by screening
• Benefit of screening = B - A (the difference in outcomes)

Key Principles

1. Screening is worthwhile only if detection precedes the final critical point - there is little value in detecting a disease if the critical window for effective treatment has already passed.
2. Screening programmes should concentrate on diseases where the time lag between onset and the final critical point is sufficiently long to make population-wide screening feasible and beneficial.
3. There is nothing to be gained by screening for diseases whose onset is quite obvious or symptomatic from the start.
4. The benefits of any detection programme must be viewed against its complexities and costs. Lead time quantifies the potential benefit in terms of improved outcomes.

Lead-Time Bias

• Screening may appear to increase survival time after diagnosis merely because disease is diagnosed earlier, not because the disease course has actually been altered.
• For example: if a cancer is detected 2 years earlier by screening but the patient dies at the same time as they would have without screening, the apparent "survival" is longer but no real benefit has occurred.
• This bias must be accounted for when assessing screening programme outcomes - improvements in stage distribution and survival from diagnosis can be misleading without correcting for lead time.

Summary (Exam Point)

Lead time = the period between detection of disease by screening and detection by usual clinical means (symptoms). It represents the head start given by screening. A longer lead time means more opportunity for effective intervention - but the benefit is real only if that time is used to treat the disease before its final critical point is reached.

• Park's Textbook of Preventive and Social Medicine, p. 155

Criteria for Screening / Screening Test - Diagnostic Criteria

Introduction

1. The DISEASE to be screened
2. The TEST to be applied

I. Criteria Related to the DISEASE

1. The condition should be an important health problem (prevalence should generally be high)
2. There should be a recognizable latent or early asymptomatic stage
3. The natural history of the condition, including progression from latent to declared disease, should be adequately understood
4. There should be a test that can detect the disease prior to the onset of signs and symptoms
5. Facilities should be available for confirmation of the diagnosis
6. There should be an effective treatment available
7. There should be an agreed-upon policy concerning whom to treat (e.g., borderline diabetes, lower ranges of blood pressure)
8. There should be good evidence that early detection and treatment reduces morbidity and mortality
9. The expected benefits (lives saved) should exceed the risks and costs

II. Criteria Related to the SCREENING TEST

1. Acceptability

• Since high cooperation is needed, the test must be acceptable to the target population
• Tests that are painful, discomforting or embarrassing (e.g., rectal or vaginal examinations) are less acceptable for mass campaigns

2. Repeatability (Reliability / Precision / Reproducibility)

• Intra-observer variation - variation between repeated observations by the same observer on the same subject at the same time
• Inter-observer variation - variation between different observers examining the same subject/material

3. Validity (Accuracy)

a. Sensitivity

The ability of a test to identify correctly all those who have the disease ("true-positives")

• Formula: Sensitivity = a / (a + c) × 100
• A 90% sensitivity means 90% of diseased persons will give a true-positive result; 10% will give false-negatives
• A highly sensitive test has few false negatives

b. Specificity

The ability of a test to identify correctly those who do NOT have the disease ("true-negatives")

• Formula: Specificity = d / (b + d) × 100
• A 90% specificity means 90% of non-diseased persons will give true-negative results; 10% will be falsely classified as diseased
• A highly specific test has few false positives

The 2×2 Table

4. Predictive Value

• Predictive value of a positive test = a / (a+b) × 100
  • Probability that a person with a positive test actually has the disease
  • Increases as disease prevalence increases; falls as prevalence declines
• Predictive value of a negative test = d / (c+d) × 100

5. False Negatives and False Positives

6. Yield

"Yield" is the amount of previously unrecognized disease diagnosed as a result of screening.

7. Combination of Tests

Summary

• Park's Textbook of Preventive and Social Medicine, pp. 156-159

Evaluation of a Screening Test

Introduction

The 2×2 Table (Foundation of Evaluation)

• a = True positives (diseased + test positive)
• b = False positives (not diseased + test positive)
• c = False negatives (diseased + test negative)
• d = True negatives (not diseased + test negative)

Measures of Evaluation

1. Sensitivity

The ability of a test to correctly identify all those who have the disease (true-positives).

• A 90% sensitivity means 90% of diseased persons will give a true-positive result; the remaining 10% give a false-negative result
• A highly sensitive test has few false negatives
• Sensitivity is low → large number of false negatives

2. Specificity

The ability of a test to correctly identify those who do NOT have the disease (true-negatives).

• A 90% specificity means 90% of non-diseased persons will give a true-negative result; 10% will be falsely classified as diseased
• A highly specific test has few false positives
• Specificity is low → large number of false positives

3. Predictive Accuracy (Predictive Value)

Reflects the diagnostic power of the test. Depends on sensitivity, specificity, AND disease prevalence.

• Probability that a person with a positive test actually has the disease
• Increases as disease prevalence increases; falls as prevalence declines
• Example: Gram-stained cervical smear for gonorrhoea - predictive value was 21%, 47%, and 63% at prevalences of 5%, 15%, and 25% respectively

• Probability that a person with a negative test truly does not have the disease

4. False Negatives and False Positives

• Epidemiologist thinks in terms of sensitivity and specificity
• Clinician thinks in terms of false negatives and false positives

5. Percentage of False Negatives and Positives

• % False negatives = c / (a + c) × 100
• % False positives = b / (b + d) × 100

Cut-off Point and Decision Making

1. Disease prevalence - When prevalence is high, set the cut-off lower to increase sensitivity
2. Nature of the disease:

• For lethal diseases (e.g., cervical cancer, breast cancer) where early detection dramatically improves prognosis → higher sensitivity is preferred, even at expense of specificity (false positives are tolerable, false negatives are not)
• For prevalent diseases where treatment does not markedly alter outcome (e.g., diabetes) → higher specificity is needed (false positives must be limited to avoid overburdening the health system)

6. Yield

"Yield" = the amount of previously unrecognized disease diagnosed as a result of screening effort.

7. Combination of Tests

• Sequential/serial testing: All screened by a high-sensitivity test first (e.g., RPR for syphilis), then positives retested by a high-specificity test (e.g., FTA-ABS) → final positives are true cases
• Parallel testing: Multiple tests done simultaneously; improves sensitivity

Summary Table

• Park's Textbook of Preventive and Social Medicine, pp. 157-161